{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:41Z","timestamp":1777934741286,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe the impact of immune checkpoint inhibitors (ICPi) in infection control in people living with HIV (PLWHIV) and to explore their safety compared with a matched cohort of people living without HIV (PLWOHIV). Secondary, to report inclusion and exclusion criteria for PLWHIV in clinical trials (CT) with ICPi.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Observational, retrospective, single-center study. PLWHIV initiating ICPi from January 2018 until June 2023 were included. Biomarkers of HIV infection control were collected at baseline and after ICPi initiation. Safety data were compared with a 1:2 matched cohort of PLWOHIV. CT with ICPi starting recruitment between January 2018 and December 2022 were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-eight PLWHIV were included, most male (22; 78.6%), median age 57 years (IQI 55.0\u201360.0). Follow-up data on infection control were available in 19 (67.9%) patients. In 17 (89.5%) the viral load was &lt;200 copies\/ml throughout the complete follow-up, in 13 (68.4%) CD4\u2009+\u2009remained above 200 cells\/\u00b5l and in 13 (68.4%) the CD4\/CD8 ratio persisted \u22650.4. In 11 (57.9%) all three conditions were met. Forty-eight PLWOHIV were identified for the matched cohort. Adverse events rates were similar between groups.<\/jats:p>\n                    <jats:p>A total of 126 CT with ICPi were identified: 91 (72.2%) explicitly excluded PLWHIV, 24 (19.0%) did not mention HIV infection, and 11 (8.7%) allowed their inclusion under certain conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ICPi in PLWHIV appeared to have a safety profile similar to that observed in PLWOHIV without evident negative effects on viral control. However, PLWHIV remain frequently excluded from ICPi CT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261430873","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T13:32:13Z","timestamp":1773495133000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitors for the treatment of cancer in people living with HIV"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9326-3198","authenticated-orcid":false,"given":"Sara","family":"Rodr\u00edguez-Tierno","sequence":"first","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-553X","authenticated-orcid":false,"given":"Jorge","family":"Fern\u00e1ndez-Fradejas","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2897-3109","authenticated-orcid":false,"given":"Manuel","family":"V\u00e9lez-D\u00edaz-Pallar\u00e9s","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-7236","authenticated-orcid":false,"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9373-6011","authenticated-orcid":false,"given":"Mar\u00eda Jes\u00fas","family":"Vivancos-Gallego","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6449-9977","authenticated-orcid":false,"given":"Ana","family":"\u00c1lvarez-D\u00edaz","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-3039","authenticated-orcid":false,"given":"Hilario","family":"Mart\u00ednez-Barros","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"e_1_3_2_2_2","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Antiretroviral Therapy Cohort Collaboration","unstructured":"Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 2017 Aug; 4: e349\u2013e356.","journal-title":"Lancet HIV"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1615896"},{"key":"e_1_3_2_4_2","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey A","unstructured":"Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV 2023 May; 10: e295\u2013e307.","journal-title":"Lancet HIV"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-018-0148-x"},{"key":"e_1_3_2_6_2","article-title":"HIV And neoplasms: what do we know so far?","volume":"21","author":"Souza TF","unstructured":"Souza TF, Sym YV, Chehter EZ. HIV And neoplasms: what do we know so far? Einstein (Sao Paulo) 2023 Jun 19; 21: eRW0231.","journal-title":"Einstein (Sao Paulo)"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32730"},{"key":"e_1_3_2_8_2","first-page":"502","article-title":"Risk of cancer in HIV-infected patients in Spain, 2004-2015. The CoRIS cohort study","volume":"37","author":"Garc\u00eda-Abell\u00e1n J","unstructured":"Garc\u00eda-Abell\u00e1n J, Del R\u00edo L, Garc\u00eda JA, et al. Risk of cancer in HIV-infected patients in Spain, 2004-2015. The CoRIS cohort study. Enferm Infecc Microbiol Clin (Engl Ed) 2019 Oct; 37: 502\u2013508. English, Spanish.","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5967"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102836"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103840"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86081-w"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02459"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11061015"},{"key":"e_1_3_2_16_2","article-title":"Immune checkpoint inhibitor therapy for cancer patients infected with HIV: a systematic review","volume":"18","author":"Luo L","unstructured":"Luo L, Xu Y, Li T. Immune checkpoint inhibitor therapy for cancer patients infected with HIV: a systematic review. Asia Pac J Clin Oncol 2022 Apr; 18: e17\u2013e22.","journal-title":"Asia Pac J Clin Oncol"},{"key":"e_1_3_2_17_2","unstructured":"National Cancer Institute. National Cancer Institute common terminology criteria for adverse Events v5.0 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_qui ck_reference_5\u2009\u00d7\u20097.pdf (2017 accessed August 2023)."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_2_19_2","volume-title":"ClinicalTrials.gov","author":"US National Library of Medicine","unstructured":"US National Library of Medicine. ClinicalTrials.gov. Bethesda, MD: US National Institutes of Health. https:\/\/clinicaltrials.gov\/ [accessed August 2023]."},{"key":"e_1_3_2_20_2","volume-title":"EU clinical trials register","author":"European Medicines Agency","unstructured":"European Medicines Agency. EU clinical trials register. Amsterdam, The Netherlands: European Medicines Agency. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search (accessed August 2023)."},{"key":"e_1_3_2_21_2","volume-title":"Registro Espa\u00f1ol de Estudios Cl\u00ednicos","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Registro Espa\u00f1ol de Estudios Cl\u00ednicos. Madrid, Espa\u00f1a: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. https:\/\/reec.aemps.es\/reec\/public\/web.html (Accessed August 2023)."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_3_2_23_2","article-title":"Impact of anti-PD-1 and anti-CTLA-4 on the human immunodeficiency virus (HIV) reservoir in people living with HIV with cancer on antiretroviral therapy: the AIDS malignancy consortium 095 study","volume":"73","author":"Rasmussen TA","unstructured":"Rasmussen TA, Rajdev L, Rhodes A, et al. Impact of anti-PD-1 and anti-CTLA-4 on the human immunodeficiency virus (HIV) reservoir in people living with HIV with cancer on antiretroviral therapy: the AIDS malignancy consortium 095 study. Clin Infect Dis 2021 Oct 5; 73: e1973\u2013e1981.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0465"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7338"},{"key":"e_1_3_2_27_2","article-title":"Examining exclusion criteria in advanced prostate cancer clinical trials: an assessment of recommendations from the American society of clinical oncology and friends of cancer research","volume":"21","author":"Ebrahimi H","unstructured":"Ebrahimi H, Castro DV, Feng MI, et al. Examining exclusion criteria in advanced prostate cancer clinical trials: an assessment of recommendations from the American society of clinical oncology and friends of cancer research. Clin Genitourin Cancer 2023 Dec; 21: e467\u2013e473.","journal-title":"Clin Genitourin Cancer"},{"key":"e_1_3_2_28_2","article-title":"Cancer immunotherapy in special challenging populations: recommendations of the advisory committee of spanish melanoma group (GEM)","volume":"9","author":"Gonzalez-Cao M","unstructured":"Gonzalez-Cao M, Puertolas T, Riveiro M, et al. Cancer immunotherapy in special challenging populations: recommendations of the advisory committee of spanish melanoma group (GEM). J Immunother Cancer 2021 Mar; 9: e001664.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_2_29_2","first-page":"41990","article-title":"Cancer clinical trial eligibility criteria: patients with HIV, hepatitis B virus, or hepatitis C virus infections","volume":"85","author":"Food and Drug Administration","year":"2020","unstructured":"Food and Drug Administration. Cancer clinical trial eligibility criteria: patients with HIV, hepatitis B virus, or hepatitis C virus infections. Federal Register 2020; 85: 41990\u201341992.","journal-title":"Federal Register"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13585"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221090199"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261430873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261430873","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261430873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:32Z","timestamp":1777689152000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261430873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":30,"alternative-id":["10.1177\/10781552261430873"],"URL":"https:\/\/doi.org\/10.1177\/10781552261430873","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"article-number":"10781552261430873"}}